• BioMark Diagnostics received patent allowances from Canadian and European patent offices for its early-stage lung cancer blood test technology.
• The IP covers metabolic signatures and an algorithm used in a minimally invasive liquid biopsy aimed at early detection of non-small cell lung cancer.
• The company cited validation across more than 15,000 blood samples from Quebec, France, and Germany.
• BioMark is pursuing related patent applications in the US, China, and Japan.
• The company is preparing a commercial launch later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMark Diagnostics Inc. published the original content used to generate this news brief on July 12, 2026, and is solely responsible for the information contained therein.